Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
98% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Equity to Asset 0.44
SGEN's Equity to Asset is ranked lower than
75% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SGEN: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.58 Max: 0.96
Current: 0.44
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
97% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 11.07
M-Score: -2.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -36.41
SGEN's Operating margin (%) is ranked higher than
57% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. SGEN: -36.41 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59  Med: -260.49 Max: -23.35
Current: -36.41
-9958.59
-23.35
Net-margin (%) -36.02
SGEN's Net-margin (%) is ranked higher than
57% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. SGEN: -36.02 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17  Med: -242.65 Max: -23.22
Current: -36.02
-7917.17
-23.22
ROE (%) -53.03
SGEN's ROE (%) is ranked lower than
64% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SGEN: -53.03 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s 10-Year ROE (%) Range
Min: -128.57  Med: -43.57 Max: -24.17
Current: -53.03
-128.57
-24.17
ROA (%) -24.64
SGEN's ROA (%) is ranked higher than
52% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. SGEN: -24.64 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s 10-Year ROA (%) Range
Min: -50.86  Med: -34.04 Max: -12
Current: -24.64
-50.86
-12
ROC (Joel Greenblatt) (%) -256.15
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. SGEN: -256.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -903.49  Med: -498.01 Max: -178.02
Current: -256.15
-903.49
-178.02
Revenue Growth (3Y)(%) 40.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SGEN: 40.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.3  Med: 39.90 Max: 157.1
Current: 40.3
7.3
157.1
EBITDA Growth (3Y)(%) -24.70
SGEN's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. SGEN: -24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2  Med: -1.65 Max: 18
Current: -24.7
-30.2
18
EPS Growth (3Y)(%) -22.70
SGEN's EPS Growth (3Y)(%) is ranked lower than
70% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. SGEN: -22.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -34  Med: -4.65 Max: 27.9
Current: -22.7
-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SGEN Guru Trades in Q3 2014

Ray Dalio 6,140 sh (New)
Manning & Napier Advisors, Inc 485,810 sh (+21.61%)
PRIMECAP Management 10,954,900 sh (+0.54%)
Columbia Wanger 5,155,000 sh (-22.01%)
» More
Q4 2014

SGEN Guru Trades in Q4 2014

PRIMECAP Management 11,178,050 sh (+2.04%)
Manning & Napier Advisors, Inc 485,810 sh (unchged)
Ray Dalio Sold Out
Columbia Wanger Sold Out
Columbia Wanger 4,474,100 sh (-13.21%)
» More
Q1 2015

SGEN Guru Trades in Q1 2015

PRIMECAP Management 11,836,575 sh (+5.89%)
Manning & Napier Advisors, Inc 492,690 sh (+1.42%)
Columbia Wanger 3,408,200 sh (-23.82%)
» More
Q2 2015

SGEN Guru Trades in Q2 2015

Vanguard Health Care Fund 170,125 sh (New)
PRIMECAP Management 11,899,100 sh (+0.53%)
Columbia Wanger 2,355,005 sh (-30.90%)
Manning & Napier Advisors, Inc 252,470 sh (-48.76%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Seattle Genetics Inc

Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) invests almost exclusively in health care companies. It’s been a successful investment niche. Vanguard enjoyed returns exceeding 28% in 2014, 43% in 2013 and 15% in 2012. Read more...

Ratios

vs
industry
vs
history
P/B 29.24
SGEN's P/B is ranked lower than
96% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SGEN: 29.24 )
Ranked among companies with meaningful P/B only.
SGEN' s 10-Year P/B Range
Min: 1.74  Med: 8.48 Max: 36.09
Current: 29.24
1.74
36.09
P/S 16.79
SGEN's P/S is ranked lower than
60% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. SGEN: 16.79 )
Ranked among companies with meaningful P/S only.
SGEN' s 10-Year P/S Range
Min: 9.98  Med: 20.45 Max: 45.83
Current: 16.79
9.98
45.83
Current Ratio 2.65
SGEN's Current Ratio is ranked lower than
66% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. SGEN: 2.65 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s 10-Year Current Ratio Range
Min: 2.65  Med: 5.14 Max: 30.03
Current: 2.65
2.65
30.03
Quick Ratio 2.29
SGEN's Quick Ratio is ranked lower than
66% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. SGEN: 2.29 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s 10-Year Quick Ratio Range
Min: 2.29  Med: 4.95 Max: 30.03
Current: 2.29
2.29
30.03
Days Inventory 444.77
SGEN's Days Inventory is ranked lower than
94% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. SGEN: 444.77 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s 10-Year Days Inventory Range
Min: 442.93  Med: 557.12 Max: 639.76
Current: 444.77
442.93
639.76
Days Sales Outstanding 53.38
SGEN's Days Sales Outstanding is ranked higher than
59% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. SGEN: 53.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s 10-Year Days Sales Outstanding Range
Min: 25.55  Med: 80.45 Max: 1028.64
Current: 53.38
25.55
1028.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 242.59
SGEN's Price/Net Cash is ranked lower than
99% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. SGEN: 242.59 )
Ranked among companies with meaningful Price/Net Cash only.
SGEN' s 10-Year Price/Net Cash Range
Min: 2.12  Med: 10.76 Max: 284.71
Current: 242.59
2.12
284.71
Price/Net Current Asset Value 41.24
SGEN's Price/Net Current Asset Value is ranked lower than
92% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. SGEN: 41.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 2.09  Med: 9.73 Max: 447
Current: 41.24
2.09
447
Price/Tangible Book 28.84
SGEN's Price/Tangible Book is ranked lower than
93% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. SGEN: 28.84 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s 10-Year Price/Tangible Book Range
Min: 1.78  Med: 5.64 Max: 33.85
Current: 28.84
1.78
33.85
Price/Median PS Value 0.81
SGEN's Price/Median PS Value is ranked higher than
67% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. SGEN: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.51  Med: 1.13 Max: 28.5
Current: 0.81
0.51
28.5
Earnings Yield (Greenblatt) (%) -2.25
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. SGEN: -2.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.44  Med: 0.00 Max: 0
Current: -2.25
-2.44
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 320 415 535
EPS($) -0.98 -0.44 -0.12
EPS without NRI($) -0.98 -0.44 -0.12

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Comment for Companies Ranked by Business Predictability Jan 03 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 

More From Other Websites
Seattle Genetics' Adcetris Label Expanded in the U.S. Aug 18 2015
Seattle Genetics drug wins FDA approval, could boost biotech's revenue Aug 18 2015
Sell Seattle Genetics' Latest Good News: Piper Jaffray Aug 18 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events Aug 17 2015
Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical... Aug 17 2015
3 Key Biotech Drug Approvals Expected This Month Aug 12 2015
Takeda Pharmaceutical Co., Ltd. Earnings Q2*, 2015 Aug 12 2015
Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter Aug 06 2015
SEATTLE GENETICS INC /WA Financials Aug 06 2015
10-Q for Seattle Genetics, Inc. Aug 01 2015
Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog Jul 31 2015
Edited Transcript of SGEN earnings conference call or presentation 30-Jul-15 8:30pm GMT Jul 31 2015
Seattle Genetics reports 2Q loss Jul 30 2015
Seattle Genetics reports 2Q loss Jul 30 2015
Seattle Genetics losses grow after deal with Boston company, R&D investments Jul 30 2015
Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today Jul 30 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
Seattle Genetics Reports Second Quarter 2015 Financial Results Jul 30 2015
Cramer: Receptos perfect fit for Celgene Jul 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK